# Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Canonical URL: https://biopharmsignal.com/news/TERN/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml
Ticker: TERN
Company: Terns Pharmaceuticals
Source: Terns Pharmaceuticals
Published: 2026-03-25 10:48 EST
Original Source URL: https://ir.ternspharma.com
## Summary

Terns’ lead candidate TERN-701 is an investigational oral  allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck

## Article Body
Terns’ lead candidate TERN-701 is an investigational oral  allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck
## Recent Company News
- 2026-04-27 12:05 EST — [Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia](https://biopharmsignal.com/news/TERN/terns-pharmaceuticals-announces-fda-breakthrough-therapy-designation-granted-to-tern-701-for-certain-patients-with-chronic-myeloid-leukemia) — Source: Terns Pharmaceuticals
- 2026-04-02 20:05 EST — [Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)](https://biopharmsignal.com/news/TERN/terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4) — Source: Terns Pharmaceuticals
- 2026-03-25 10:48 EST — [Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)](https://biopharmsignal.com/news/TERN/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml) — Source: Terns Pharmaceuticals
- 2026-02-25 21:05 EST — [Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences](https://biopharmsignal.com/news/TERN/terns-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences) — Source: Terns Pharmaceuticals
- 2026-01-07 21:05 EST — [Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference](https://biopharmsignal.com/news/TERN/terns-pharmaceuticals-to-highlight-2026-priorities-and-program-milestones-at-the-44th-annual-j-p-morgan-healthcare-conference) — Source: Terns Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)